Alzheimer's Disease

Advances in Etiology, Pathogenesis and Therapeutics
Herausgeber: Iqbal, Khalid; Winblad, Bengt; Sisodia, Sangram S

• Gebundenes Buch

Produktbeschreibung

Alzheimer's Disease is an ever-present problem affecting millions of people around the world and, as people's average lifespan lengthens, its prevalence is set to increase. A global effort is needed to combat the disease, including research to investigate the causes, development of effective treatments and, ultimately, prevention of the disease. Published every two years, these timely books discuss the very latest research. This new volume in the series: * Provides a uniques source of reference to the important work being done in this field * Gives academics and clinicians an opportunity to learn about cutting edge developments * Covers all aspects of Alzheimer's Disease, including diagnosis, clinical course, epidemiological course and therapeutics and disease mechanisms. Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics and Therapeutics will provide essential information for basic and clinical researchers in Alzheimer's Disease and other dementias as well as for those who care for patients.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Wiley
• Seitenzahl: 888
• Erscheinungstermin: 24. August 2001
• Englisch
• Abmessung: 231mm x 157mm x 55mm
• Gewicht: 1275g
• ISBN-13: 9780471521761
• ISBN-10: 0471521760
• Artikelnr.: 24501849

Autorenporträt

Khalid Iqbal is the editor of Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics, published by Wiley. Sangram S. Sisodia is the editor of Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics, published by Wiley. Bengt Winblad is the editor of Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics, published by Wiley.

Inhaltsangabe

List of Contributors xii Dedications xxvi Scientists Honored for Pioneering Research xxix Preface xxxv Acknowledgments xxxvi I. EPIDEMIOLOGY AND RISK FACTORS 1 1. The Transition from Normal Functioning to Dementia in the Aging Population 3 Laura Fratiglioni
Brent Small
Bengt Winblad and Lars Bäckman 2. Epidemiology of Alzheimer's Disease and Dementia: Advances and Challenges 11 Robert Katzman 3. Epidemiology of Dementia in Down's Syndrome 23 Nicole Schupf II. GENETICS 31 4. A Genomic Search for Alzheimer's Disease Genes 33 Jonathan L. Haines
L. Renee Bailey
Janet M. Grubber
Dale Hedges
Jenifer L. Hall
Sandra West
Leonard Santoro
Beth Kemmerer
Anne M. Saunders
Allen D. Roses
Gary W. Small
William K. Scott
P. Michael Conneally
Jeffery M. Vance and Margaret A. Pericak-Vance 5. Candidate Genes Showing No Evidence of Association with Alzheimer's Disease: Results of the NIMH-AD Genetics Initiative 45 Lars Bertram
Deborah Blacker
Adam S. Crystal
Jennifer Jones
Devon Keeney
Laura A. MacKenzie-Ingano
Kristina Mullin
Sanjay Basu
Stephen Yhu
Melvin McInnis
Rodney C. P. Go
Aleister J. Saunders and Rudolph E. Tanzi 6. Familial Alzheimer's Disease with Spastic Paraparesis Associated with a Mutation at Codon 261 of the Presenilin 1 Gene 53 Martin R. Farlow
Jill R. Murrell
Frederick W. Unverzagt
Michael Phillips
Masaki Takao
Christine Hulette and Bernardino Ghetti 7. Genetic Analysis of the Presenilin Pathway in Drosophila 61 Izhar Livne-Bar and Gabrielle L. Boulianne 8. Molecular Genetics and Transgenic Modeling of the Tauopathies 71 Jada Lewis
Matt Baker
Marjon Van Slegtenhorst and Mike Hutton 9. Regulation of Four-repeat tau Expression: Interactions between Exon and Intron Splicing Regulatory Sequences 87 Ian D'Souza and Gerard D. Schellenberg III. DIAGNOSIS AND CLINICAL COURSE 97 10. Preclinical Prediction of AD: Relation Between Neuropsychological and Neuroimaging Findings 99 Marilyn S. Albert
Ronald J. Killiany
Keith Johnson
Rudolph E. Tanzi and Kenneth Jones 11. Neuropsychological Detection of Preclinical Alzheimer's Disease: Results of a Neuropathological Series of 'Normal' Controls 111 Kathleen A. Welsh-Bohmer
Christine Hulette
Donald Schmechel
James Burke and Ann Saunders 12. Potentially Reversible Conditions in Memory Clinic Patients 123 Anne-Mette Hejl
Peter Høgh and Gunhild Waldemar 13. The Alzheimer's Disease Centers' Neuropsychological Database Initiative: A Resource for Alzheimer's Disease Prevention Trials 129 Michael Grundman
Hyun T. Kim
David Salmon
Martha Storandt
Glenn Smith
Steven Ferris
Richard Mohs
Jason Brandt
Rachelle Doody
Kathleen Welsh-Bohmer
Judith Saxton
Kathy Saine
Frederick Schmitt
Paula Ogrocki
Nancy Johnson
Diane Howieson
Michelle Papka
Joanne Green
Anthony Gamst
Walter Kukull and Leon J. Thal
for the Alzheimer's Disease Centers' Neuropsychological Database Initiative 14. Mild Cognitive Impairment: Transition from Aging to Alzheimer's Disease 141 Ronald C. Petersen 15. Brain Functional Imaging in Early and Preclinical Alzheimer's Disease 153 Agneta Nordberg
Vesna Jelic
Eva Arnáiz
Bengt Långström and Ove Almkvist 16. Amyloid
PHF-tau
Ubiquitin and Synaptic Markers in the Progression of Alzheimer's Disease: Immunochemical Analyses of Frontal Cortex from Prospectively Studied Elderly Humans 165 D. S. Wang
E. Cochran
D. Bennett
E. Mufson
C. Eckman and D. W. Dickson 17. Imaging the Consequences of Alzheimer's Disease Pathology 181 Yaakov Stern and Scott Small 18. Influence of apoE Genotype and PET Brain Imaging on Preclinical Prediction of Alzheimer's Disease 193 Gary W. Small
Linda M. Ercoli
Daniel H.S. Silverman
S.-C. Huang
Susan Y. Bookheimer
Helen Lavretsky
Karen Miller
Prabha Siddarth
John C. Mazziotta
Ann M. Saunders
Margaret A. Pericak-Vance
Allen D. Roses
Jorge R. Barrio and Michael E. Phelps 19. Overview of Vascular Dementia 205 William R. Markesbery 20. Clinical and Imaging Characteristics of Vascular Dementia in a Memory Clinic 219 F. Pasquier
X. Douay
C. Delmaire
F. Lebert and J. P. Pruvo 21. MRI of Entorhinal Cortex and Hippocampus in Alzheimer's Disease
Subcortical Ischemic Vascular Dementia and Mixed Dementia 229 N. Schuff
A. T. Du
D. Amend
Y. Y. Hsu
M. P. Laakso
W. Jagust
H. C. Chui and M. W. Weiner 22. Olfactory Function and Event-related Potentials in Alzheimer's Disease 237 Claire Murphy and Charlie D. Morgan 23. Phenotypic Differences in Cholinergic Markers within the Nucleus Basalis in Individuals with Mild Cognitive Impairment 253 Elliott J. Mufson
Michele Gilmor
Shuang Y. Ma
Alan I. Levey and Jeffrey H. Kordower 24. Evaluating CNS Biomarkers for Alzheimer's Disease 265 John H. Growdon 25. CSF Markers for Early Alzheimer's Disease 275 Kaj Blennow
Pia Davidsson and Eugeen Vanmechelen 26. CSF-Phospho-tau (181P) as a Promising Marker for Discriminating Alzheimer's Disease from Dementia with Lewy Bodies 285 E. Vanmechelen
E. Van Kerschaver
K. Blennow
P. P. De Deyn
D. Galasko
L. Parnetti
C. J. M. Sindic
H. Arai
M. Riemenschneider
H. Hampel
H. Pottel
A. Valgaeren
F. Hulstaert and H. Vanderstichele 27. Increased Levels of a Minor Glycoform of Acetylcholinesterase in Alzheimer's Disease Brain and Cerebrospinal Fluid 293 Javier Sáez-Valero
Su San Mok
Lisa Fodero
Alberto Marcos
Maria-Sagrario Barquero
Catriona McLean and David H. Small 28. Plasma b-Amyloid as a Surrogate Genetic Marker in Late-onset Alzheimer's Disease 303 Nilufer Ertekin Taner
Neill Graff-Radford
Linda H. Younkin
Christopher Eckman
Jennifer Adamson
Daniel J. Schaid
John Blangero
Michael Hutton and Steven G. Younkin 29. Levels of Total and Deposited Ab are Correlated with Dementia 311 S. Parvathy
J. Naslund
V. Haroutunian and J. D. Buxbaum 30. What Should We Tell Patients Attending a Memory Disorders Clinic About Their Diagnosis? 319 Conor P. Maguire and Rebecca M. Slinn IV. MECHANISMS OF NEURODEGENERATION 329 31. Innate Immunity
Autotoxicity and Degenerative Neurologies 331 Patrick L. McGeer
Koju Yasojima and Edith G. McGeer 32. Neuroinflammatory Responses in the Alzheimer's Disease Brain Promote the Oxidative Post-translational Modification of Amyloid Deposits 341 Craig S. Atwood
Xudong Huang
Robert D. Moir
Mark A. Smith
Rudolph E. Tanzi
Alex E. Roher
Ashley I. Bush and George Perry 33. Plasma Antioxidants and Oxidative DNA Damage in Lymphocytes from Normal Aged People and Alzheimer's Disease Patients 363 Patrizia Mecocci
Maria Cristina Polidori
Tiziana Ingegni
Paola Mattioli
Antonio Cherubini
Marco Catani
Roberta Cecchetti and Umberto Senin 34. Oxidative Damage and Antioxidant Responses in Alzheimer's Disease 371 George Perry
Akihiko Nunomura
Jesus Avila
Mar Perez
Catherine A. Rottkamp
Craig S. Atwood
Xiongwei Zhu
Gjumrakch Aliev
Adam D. Cash and Mark A. Smith 35. Cyclooxygenase (COX)-2 and Clinical Progression of Alzheimer's Disease Dementia: Implications in the Role of Neuronal COX-2 in Cell Cycle 379 Giulio Maria Pasinetti 36. Parallels between the Redox Properties and Toxicity of Ab in Alzheimer's Disease and Mutant Cu/Zn-SOD in Familial Amyotrophic Lateral Sclerosis 393 Ashley I. Bush 37. b-Amyloid Toxicity: Diverse Biological Activities Drive Multiple Cellular Mechanisms 407 C. W. Cotman
L. Tong
A. Anderson
D. Cribbs and J. Su 38. Mechanisms of Ab Production and Ab Degradation: Routes to the Treatment of Alzheimer's Disease 421 D. J. Selkoe
W. Xia
W. T. Kimberly
K. Vekrellis
D. Walsh
W. P. Esler and M. S. Wolfe 39. A High Fat
High Cholesterol Diet Accelerates b-Amyloid Accumulation in the CNS of a Transgenic Mouse Model of Alzheimer's Disease 433 Lorenzo M. Refolo
Brian Malester
John LaFrancois
Tara Bryant-Thomas
Rong Wang
G. Stephen Tint
Kumar Sambamurti
Karen Duff and Miguel A. Pappolla 40. Electron Microscopy and X-ray Diffraction Studies further Confirm the Efficacy of PTI-00703TM1 (Cat's Claw Derivative) as a Potential Inhibitor of Alzheimer's b-Amyloid Protein Fibrillogenesis 449 Gerardo M. Castillo
Daniel A. Kirschner
Ann G. Yee and Alan D. Snow 41. Accelerated Ab Generation in a Cell Model of Alzheimer's Disease-related Endosomal-Lysosomal System Upregulation 461 Paul M. Mathews
Carolyn B. Guerra
Ying Jiang
Benjamin H. Kao
Ravi Dinakar
Pankaj Mehta
Anne M. Cataldo and Ralph A. Nixon 42. The Amyloid Precursor Protein V717I Mutation Increases Susceptibility to Cell Death in a Cholesterol-dependent Manner 469 Luigi Puglielli
Laura A. MacKenzie Ingano
Rudolph E. Tanzi and Dora M. Kovacs 43. Intracellular and Secreted Ab42/40 Ratios Are Differently Influenced by APP Mutations 479 Heike S. Grimm
Stefan F. Lichtenthaler
Konrad Beyreuther and Tobias Hartmann 44. Familial British Dementia 487 Jorge Ghiso
Tamas Révész
Agueda Rostagno
Ruben Vidal
Gordon Plant and Blas Frangione 45. Cellular Metabolism of Familial British Dementia-associated BRI-L 495 Seong-Hun Kim and Sangram S. Sisodia 46. A Decamer Duplication in the BRI Gene Originates a de novo Amyloid Peptide that Causes Dementia in a Danish Kindred 507 Ruben G. Vidal
Tamas Révész
Agueda Rostagno
Toke Bek
Hans Braendgaard
Gordon Plant
Jorge Ghiso and Blas Frangione 47. Familial Alzheimer's Disease-linked Mutant Presenilins Attenuate Capacitative Calcium Entry 515 Isaac Cheng
Andrew S. Yoo
Rudolph E. Tanzi and Tae-Wan Kim 48. Presenilin-1 Is a Regulatory Component of the Cadherin Cell Adhesion Complex: Implications for Alzheimer's Disease 521 Anastasio Georgakopoulos
Philippe Marambaud
Nikolaos K. Robakis and Lia Baki 49. Presenilins and Notch Signaling Pathway 531 Weihong Song and Bruce A. Yankner 50. Functional Consequences of the Association of PS1 with b-Catenin 541 Salvador Soriano
David E. Kang
Nathalie Chevallier
Hui Zheng and Edward H. Koo 51. A Novel Protease Active Site Motif Conserved in Presenilins and Polytopic Bacterial Aspartyl Proteases? 549 Harald Steiner and Christian Haass 52. The Unfolded Protein Response-mediated Upregulation of BiP and CHOP Is not Affected by Presenilin Expression 559 Naoyuki Sato and Gopal Thinakaran 53. Mechanisms of a-Synuclein and NAC Fibrillogenesis 569 Makoto Hashimoto
Edward Rockenstein
Takato Takenouchi
Margaret Mallory and Eliezer Masliah 54. Neurofibrillary Degeneration: Patterns of Tau Isoform Expression 587 André Delacourte 55. Phosphorylation
Microtubule Binding and Aggregation of Tau Protein in Alzheimer's Disease 601 Jesús Ávila
José J. Lucas
Filip Lim
Mar Pérez
Félix Hernández
Montserrat Arrasate
Rosario Armas Portela
Elsa Champion
George Perry
Mark A. Smith and Javier Díaz Nido 56. Phosphorylation of Protein Tau and Rescue of Protein Tau-induced Axonopathy by GSK-3b in GSK-3b6htau40 Double Transgenic Mice 609 Kurt Spittaels
Chris Van den Haute
Jo Van Dorpe
Hugo Geerts and Fred Van Leuven 57. Pathogenic Implication of Altered Tau Properties Caused by FTDP-17 Mutations 621 P. Nacharaju
S. Yen
M. DeTure
C. Easson
M. Hutton and S.-H. Yen 58. A Hexapeptide Motif (306VQIVYK311)-forming b Structure Induces the Aggregation of Tau Protein to Paired Helical Filaments 631 M. von Bergen
J. Biernat
E.-M. Mandelkow and Eckhard Mandelkow V. ANIMAL AND CELLULAR MODELS 641 59. Formation of Neurofibrillary Tangles in Mouse Brain 643 Akihiko Takashima and Kentaro Tanemura 60. Inducible Transgenic Expression of Wild-type tau in H4 Neuroglioma Cells 651 Michael DeTure
Li-Wen Ko
Colin Easson
Mike Hutton and Shu-Hui Yen 61. Lewy-like Pathology in Mice Transgenic for Mutant (A53T) and Wild-type Human a-Synuclein 661 Bernd Sommer
Samuel Barbieri
Katja Hofele
Karl-Heinz Wiederhold
Alphonse Probst
Claudia Mistl
Simone Danner
Sabine Kauffmann
Willibrordus Spooren
Markus Tolnay
Graeme Bilbe and Herman van der Putten 62. Somal and Neuritic Accumulation of the Parkinson's Disease-associated Mutant [A30P]a-Synuclein in Transgenic Mice 671 Phillipp J. Kahle
Manuela Neumann
Laurence Ozmen
Hans A. Kretzschmar and Christian Haass 63. Ex vivo Transmission of Mouse-adapted Prion Strains to N2a and GT1-7 Cell Lines 679 Sylvain Lehmann
Hubert Laude
David A. Harris
Richard I. Carp
Didier Vilette
Shigeru Katamine
Jean-Yves Madec and Noriyuki Nishida 64. In Vivo Perturbation of Lysosomal Function Promotes Neurodegeneration in the PS1M146V/APPK670N
M671L Mouse Model of Alzheimer's Disease Pathology 687 Ralph A. Nixon
Paul M. Mathews
Anne M. Cataldo
Panaiyur S. Mohan
Stephen D. Schmidt
Karen Duff
Martin Berg
Neville Marks
Corinne Peterhoff and Henry Sershen 65. Changes in Cognitive Characteristics of Tg(APP)CRND8 Mice at Early Stages of Immunization with Beta-Amyloid Peptide 697 Christopher Janus
Jacqueline Pearson
Patrick Horne
Richard Renlund
Karen Parisien
Azhar Chishti
Donna Heslin
Catherine Bergeron
Paul Fraser
Peter St George-Hyslop and David Westaway VI. THERAPEUTICS AND THERAPEUTIC STRATEGIES 705 66. Galantamine
a Novel Treatment for Alzheimer's Disease: A Review of Long-term Benefits to Patients and Caregivers 707 Pierre Tariot and Bengt Winblad 67. Benefits of Donepezil on Cognition
Function and Neuropsychiatric Symptoms in Patients with Mild and Moderate Alzheimer's Disease over One Year 725 Gunhild Waldemar
Bengt Winblad
Knut Engedal
Hilkke Soininen
Frans Verhey
Anders Wimo
Anne-Lena Wetterholm
Richard Zhang
Anders Haglund
Ponni Subbiah and the Donepezil Nordic Study Group 68. Characterization of Alzheimer's b-Secretase Protein BACE: Processing and Other Post-translational Modifications 739 Mitsuru Haniu
Brian D. Bennett
Paul Denis
Yunjen Young
Elizabeth A. Mendiaz
Janis Fuller
John O. Hui
Steven Kahn
Safura Babu-Khan
Sandra Ross
Teresa Burgess
Viswanatham Katta
Margery Nicolson
Jonathan Lull
Shue-Yuan Wang
Gary Rogers
Robert Vassar and Martin Citron 69. Androgen Treatment Reduces Cognitive Deficits in Female apoE4 Transgenic Mice Jacob Raber
Anthony LeFevour and Lennart Mucke 70. Studies with the Memory-enhancing Drug AIT-082 in PC12 Cells 747 Debomoy K. Lahiri
Yuan-Wen Ge and Martin R. Farlow 71. Generation of Auto-antibodies toward Alzheimer's Disease Vaccination 759 Beka Solomon and Dan Frenkel 72. Toward the Identification of c-Secretase: Using Transition State Analog Inhibitors 777 William P. Esler
W. Taylor Kimberly
Beth L. Ostaszewski
Weiming Xia
Dennis J. Selkoe and Michael S. Wolfe 73. Photoactivated
Active-site-directed g-Secretase Inhibitors Covalently Label Presenilin 1 789 Stephen J. Gardell
Yue-Ming Li
Min Xu
Ming-Tain Lai
Qian Huang
Jose L. Castro
Jillian DiMuzio-Mower
Timothy Harrison
Colin Lellis
Alan Nadin
Joseph G. Neduvelil
R. Bruce Register
Mohinder K. Sardana
Mark S. Shearman
Xiao-Ping Shi
Adrian L. Smith
Kuo-Chang Yin and Jules A. Shafer 74. Functional Analysis of b-Secretase Using Mutagenesis and Structural Homology Modeling 799 Gwen Tatsuno
John Anderson
Jin Hong
David A. Agard
Nobuyuki Ota
Sukanto Sinha
Guriqbal Basi and Lisa McConlogue 75. Therapeutic Approaches to Prion Diseases: In Vitro Studies with Tetracycline Compounds 809 Tazeen Awan
Gianluigi Forloni
Enzio Ragg
Selina Iussich
Giacomina Rossi
Laura Colombo
Laura Girola
Tania Massignan
Orso Bugiani
Mario Salmona and Fabrizio Tagliavini VII. PSYCHOSOCIAL CARE 821 76. Influence of a Memory Training Program on Attention and Memory Performance of Patients with Dementia 823 Tanja Bernhardt
Konrad Maurer and Lutz Frölich 77. Prediction of Use of Emergency Community Services by Cognitively Impaired Seniors who Live Alone: Preliminary Findings of a Prospective Study 833 Mary C. Tierney
Jocelyn Charles
W. Gary Snow
John P. Szalai
Susan Jaglal
Franca Spizzirri and Rory H. Fisher Index 835